pharma · 2019-nCoV Pneumonia
Tongji Hospital
Tongji Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include 2019-nCoV Pneumonia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this ent
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
ASC09F+Oseltamivir
Phase 3 · small molecule · 2019-nCoV Pneumonia
ASC09F+Oseltamivir for 2019-nCoV Pneumonia is a Phase 3 program (small_molecule) at Tongji Hospital with 1 ClinicalTrials.gov record(s).
Internal code ASC09F-CTP-TJ-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tongji Hospital
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- 2019-nCoV Pneumonia
- Status
- active
- Trials
- 1